Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

Executive Summary

FDA will have a total of 12 months to review 351(k) applications and additional time to schedule certain product development meetings under the Biosimilar User Fee Act II agreement; measures to enhance management of user fee resources and improve hiring will carry over from PDUFA VI.


Related Content

US FDA's Patrick Frey Joins List Of Agency Leadership Departures
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
US FDA Sets 'Low Bar' For Meetings With Patients
ANDA Pre-Submission Meetings A 'Challenge' To Integrate Into Development Timelines
Biosimilar Development Meetings At US FDA Not Just For Talking Similarity
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015
Biosimilars Reviews Could Be Extended Two Months In BsUFA II





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts